Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis-Reference-Cited by-同舟云学术

Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis

Published:2024-04-10 Issue:5 Volume:40 Page:827-837
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Miyazaki Naoki¹^ORCID,Iwasaki Toshiki¹^ORCID,Sakai Hitomi²^ORCID,Watanuki Rurina³^ORCID,Tanizawa Yoshinori⁴^ORCID,Cai Zhihong⁴^ORCID,Kawaguchi Tsutomu⁴^ORCID,Tsurutani Junji²^ORCID,Nagashima Kengo¹^ORCID

Affiliation:

1. Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan

2. Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan

3. Department of Breast Surgery, National Cancer Center Hospital East, Kashiwa, Japan

4. Japan Drug Development and Medical Affairs, Eli Lilly Japan, Kobe, Japan

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2332436

Reference67 articles.

1. NCI. General Information About Breast Cancer. 2023. [cited 2023 Feb 9]. Available from: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq#section/_1.

2. IARC. Cancer Today. 2020. [cited 2023 Feb 9]. Available from: https://gco.iarc.fr/today/home.

3. Past trends and future estimation of annual breast cancer incidence in Osaka, Japan;Toyoda Y;Asian Pac J Cancer Prev,2016

4. Comparison of Breast Cancer Mortality in Five Countries: France, Italy, Japan, the UK and the USA from the WHO Mortality Database (1960–2000)

5. Recent Improvement in the Long-term Survival of Breast Cancer Patients by Age and Stage in Japan